Marea reports first patient dosed in MAR002 acromegaly trial

Marea Therapeutics announced October 5 that the first patient has been dosed in a Phase 2 trial of MAR002, an experimental antibody targeting the growth hormone receptor in acromegaly. The study moves the candidate into testing in people with the disease, where researchers must determine whether its hormonal effects translate into useful disease control with acceptable safety.

Marea, a subsidiary of Lisata Therapeutics, did not disclose the actual dosing date. The announcement reports a development milestone, with no Phase 2 efficacy results. MAR002 remains investigational.

What the trial will examine

The company plans to enroll approximately 72 participants across three MAR002 treatment groups and a placebo group. Its October 5 announcement describes measuring reductions in insulin-like growth factor 1, or IGF-1, after 10 weeks of treatment. Eligible participants completing that period may enter an open-label extension.

The public trial listing for TROUGH-2, identified as NCT07641179, describes a multicenter, randomized, double-blind, placebo-controlled study evaluating safety, tolerability, drug exposure and biological effects in participants with acromegaly. Randomization and masking should help researchers distinguish treatment effects from differences between participants and expectations about receiving an experimental medicine.

The extension could provide additional observations during continued treatment. However, an open-label phase lacks the same protection against bias as a blinded comparison, and a study of this size cannot settle questions about uncommon adverse effects.

Why the hormonal target matters

Acromegaly develops when the body produces excessive growth hormone, usually because of a pituitary tumor. Growth hormone stimulates production of IGF-1, which contributes to abnormal tissue growth and metabolic changes.

The consequences extend beyond enlarged hands, feet and facial features. The National Institute of Diabetes and Digestive and Kidney Diseases identifies diabetes, hypertension, heart disease, sleep apnea and arthritis among the condition's complications. That burden makes sustained disease control relevant to both everyday function and long-term health.

MAR002 is a monoclonal antibody designed to block the growth hormone receptor. This approach aims to interrupt the signal that drives IGF-1 production. It therefore addresses a defined endocrine disease mechanism; these studies do not test a general longevity intervention.

Earlier evidence came from healthy volunteers

On June 15, Marea reported Phase 1 findings presented at the Endocrine Society's annual meeting. That randomized, blinded, placebo-controlled study involved healthy adult men receiving single ascending doses, rather than patients with acromegaly undergoing repeated treatment.

The sponsor reported dose-dependent IGF-1 reductions, with peak suppression reaching 64%, and no serious adverse events or dose-limiting toxicities. Those findings support biological activity in the studied setting. They do not establish how often patients will achieve adequate disease control, how durable that control will be or what adverse effects could emerge with longer exposure.

The company's earlier discussion of potentially less frequent administration also remains a development proposition. Drug persistence in healthy volunteers does not by itself establish a convenient, effective long-term treatment schedule for patients.

What would make the next results meaningful

A reduction in IGF-1 would be relevant to the intended mechanism, but interpretation will depend on the size and consistency of the response, the proportion of patients reaching appropriate levels and the accompanying safety findings. Symptoms, treatment burden and durability will also matter when assessing practical value.

For now, the announcement establishes progress toward answering those questions. It provides no evidence that MAR002 outperforms existing therapies, prevents cardiovascular complications or improves survival.